Retatrutide studies
337 journal papers mention Retatrutide in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.
Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether Retatrutide is safe, effective or approved for any use.
- Papers
- 337
- 211 articles, 126 reviews
- Earliest paper
- 2019
- Most papers in 2026 (163)
- Open access
- 67%
- free to read somewhere
- Reviews
- 37%
- of all papers listed
What kind of studies
Of 214 papers in PubMed that mention Retatrutide in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.
- Randomized controlled trials10
- Other clinical trials1
- Meta-analyses and systematic reviews23
- Other reviews131
- Case reports3
- Animal studies only11
- Studies in humans129
Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).
Registered clinical studies
Studies on ClinicalTrials.gov that mention Retatrutide in their intervention details. A registration says a study is planned or running, not what it found.
- Registered
- 34
- Completed
- 22
- Ongoing or planned
- 11
- Phase 1
- 15
- Phase 2
- 4
- Phase 3
- 14
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390Active, not recruitingPhase 3started 2024-04-30
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028RecruitingPhase 3started 2025-10-15
- A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
NCT06982859Active, not recruitingPhase 1started 2025-06-02
- Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722Active, not recruitingPhase 3started 2024-02-21
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
NCT07035093Active, not recruitingPhase 3started 2025-05-29
The five most recently updated studies. See all 34 on ClinicalTrials.gov. Source: ClinicalTrials.gov (U.S. National Library of Medicine). Studies are found by the compound's name, so a few may be about something else.
Papers per year
2019 to 2026, peak 163 papers in a year. The latest year may still be incomplete.
Where it is published
- Diabetes22 papers
- Diabetes Obesity and Metabolism8 papers
- Cureus7 papers
- Quality in Sport7 papers
- International Journal of Innovative Technologies in Social Science6 papers
The papers
Most citedName in the title
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Tamer Coşkun, Shweta Urva, William C. Roell et al. · Cell Metabolism · 2022
Animal studyOpen access · CC BY-NC-ND316 citationsRead the open copy →
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Arun Jayant Sanyal, Lee M. Kaplan, Juan P. Frías et al. · Nature Medicine · 2024
Randomized trial · Phase 2Open access · CC BY315 citationsRead the open copy →
- Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials
K. Giblin, Lee M. Kaplan, Virend Kristen Somers et al. · Diabetes Obesity and Metabolism · 2025
Study in humansOpen access · CC BY-NC34 citationsRead the open copy →
- Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide
Wenzhuo Li, Qingtong Zhou, Zhaotong Cong et al. · Cell Discovery · 2024
Open access · CC BY32 citationsRead the open copy →
- Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence
Muhammad Naeem, Laiba Imran, Umm E Salma Shabbar Banatwala · Health Science Reports · 2024
Open access · CC BY30 citationsRead the open copy →
- Retatrutide—A Game Changer in Obesity Pharmacotherapy
Vasiliki K. Katsi, Georgios Koutsopoulos, Christos Fragoulis et al. · Biomolecules · 2025
ReviewOpen access · CC BY29 citationsRead the open copy →
- The novel GIP , GLP ‐1 and glucagon receptor agonist retatrutide delays gastric emptying
Shweta Urva, Libbey S. O’Farrell, Yu Du et al. · Diabetes Obesity and Metabolism · 2023
Study in humansOpen access · CC BY-NC-ND28 citationsRead the open copy →
- Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials
Alaa Abdrabou Abouelmagd, Amro Mamdouh Abdelrehim, Mohamed Nabih Bashir et al. · Baylor University Medical Center Proceedings · 2025
ReviewOpen access25 citationsRead the open copy →
- The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity
Hiddo J.L. Heerspink, Zeqing Lu, Yu Du et al. · Kidney International Reports · 2025
Open access · CC BY-NC-ND23 citationsRead the open copy →
- Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA
Binayak Sinha, Samit Ghosal · Obesity · 2025
Systematic reviewOpen access19 citationsRead the open copy →
- Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP
Xin Cui, Yueming Zhu, Lidan Zeng et al. · Advanced Science · 2025
Study in humansOpen access · CC BY17 citationsRead the open copy →
- Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression
Sandesh J. Marathe, Emily W. Grey, Margaret Sue Bohm et al. · npj Metabolic Health and Disease · 2025
Open access · CC BY15 citationsRead the open copy →
- Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials
Eric Pasqualotto, Rafael Oliva Morgado Ferreira, Matheus Pedrotti et al. · Metabolism Open · 2024
ReviewOpen access · CC BY15 citationsRead the open copy →
- Decreases in circulating ANGPTL3 /8 concentrations following retatrutide treatment parallel reductions in serum lipids
Yi Wen, Deven Lemen, Yanzhu Lin et al. · Diabetes Obesity and Metabolism · 2025
Clinical trial · Phase 2Open access · CC BY-NC9 citationsRead the open copy →
- The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities
Nila Ganamurali, Sarvesh Sabarathinam · Clinical Pharmacology in Drug Development · 2026
ReviewOpen access · Public domain8 citationsRead the open copy →
- Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial
IRIS A. GOETZ, Chisom Kanu, Anastasia Hoover et al. · Obesity Pillars · 2025
Open access · CC BY-NC-ND8 citationsRead the open copy →
- Inotropic effects of retatrutide in isolated human atrial preparations
Joachim Neumann, Undine Ahlrep, Britt Hofmann et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 2025
Study in humansOpen access · CC BY7 citationsRead the open copy →
- Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia
Timothy M. Piatkowski, Alison Craven, Samuel Cornell et al. · Drug and Alcohol Review · 2026
Open access5 citationsRead the open copy →
- Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease
Hiddo J.L. Heerspink, Daniël H. van Raalte, Petter Bjornstad et al. · Nephrology Dialysis Transplantation · 2025
Study in humansOpen access · CC BY5 citationsRead the open copy →
- Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair
Qingyang Li, Weilun Cheng, Lei Zhang et al. · Diabetology & Metabolic Syndrome · 2026
Open access · CC BY-NC-ND4 citationsRead the open copy →
- Retatrutide Shows Multiple Metabolic Benefits in Diet‐Induced Obese MASH Mouse and Hamster Models
François Briand, Camille Le Cudennec, E. Grasset et al. · Obesity · 2026
Animal studyOpen access · CC BY4 citationsRead the open copy →
- Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge
Greta Viebahn, Amit Khurana, Linton Freund et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 2025
Animal studyOpen access · CC BY4 citationsRead the open copy →
LatestName in title or abstract
- Suspected Drug-Induced Hepatocellular Injury Following Use of an Unregulated Injectable Product Marketed as Retatrutide: A Case Report
Ahmed Elhassan, Isra Ali, Abu-Bekr Mohamed et al. · Cureus · 2026
Open accessRead the open copy →
- EMERGING PHARMACOLOGICAL STRATEGIES IN OBESITY: FROM GLP-1 AGONISTS THROUGH TRIPLE INCRETIN THERAPY TO AMYLIN ANALOGS – NARRATIVE REVIEW
Dagmara Laufer, Olga Klimczak, Filip Chodań et al. · Archiv Euromedica · 2026
ReviewOpen accessRead the open copy →
- Eficácia e segurança da retatrutida, agonista triplo dos receptores de GIP, GLP-1 e glucagon, na obesidade e no diabetes mellitus tipo 2: Uma Revisão Sistemática
João Pedro Medina Patrício, Isadora Brasil Fraga, Maria Eduarda Candido Santos et al. · Journal of Medical and Biosciences Research. · 2026
Open access · CC BYRead the open copy →
- From Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism
Héctor Iván Saldívar-Cerón, Daniela Maldonado-Trejo, Quetzal Chavez-Castañeda et al. · International Journal of Molecular Sciences · 2026
Open access · CC BYRead the open copy →
- Glucose-dependent insulinotropic polypeptide (GIP) signaling in visceral and subcutaneous adipose tissue: implications for obesity and metabolic disease—a narrative review with a structured literature search
Joanna Smarkusz-Zarzecka, Marcelina Radziszewska, Krzysztof Ksawery Gofron et al. · Reviews in Endocrine and Metabolic Disorders · 2026
ReviewOpen access · CC BY-NC-NDRead the open copy →
- GLP-1 RECEPTOR AGONISTS AND THYROID DISEASE: FROM MECHANISM TO CLINICAL PRACTICE
Aleksandra Milewska, Anna Bociąg, Konrad Kowalski et al. · International Journal of Innovative Technologies in Social Science · 2026
Open access · CC BYRead the open copy →
- Retatrutide treatment in streptozotocin-induced diabetic rats: renal inflammatory cytokines, HIF‑1α expression, and histopathological injury profile
Ulya Keskin, Eslem Altın, Fikriye Yasemin Özatik et al. · Journal of Molecular Histology · 2026
Animal studyOpen access · CC BYRead the open copy →
- GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?
Ademir Carvalho Leite, Howard Lopes Ribeiro · Acta Diabetologica · 2026
ReviewOpen access · CC BYRead the open copy →
- Incretin-Based Polypharmacology and the Redefinition of Cardiometabolic Medicine
Sujit B. Kanoia, Anuansh Tiwari, Syed Wajahat Abbas Rizvi et al. · Journal of Pharmaceutical and Biopharmaceutical Research · 2026
Open access · CC BY-NCRead the open copy →
- Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide
Neil K. R. Sehgal, Jena Shaw Tronieri, Benjamin M. Rader et al. · JAMA Network Open · 2026
Open accessRead the open copy →
- From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease
Christiano Argano, Dalila Maggio, Chiara Pollicino et al. · Frontiers in Pharmacology · 2026
ReviewOpen access · CC BYRead the open copy →
- The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications
Zhiyu Chen, Ying Zhou, Gang Li et al. · Journal of Diabetes & Metabolic Disorders · 2026
ReviewOpen accessRead the open copy →
- Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective
Ishtiaque Ahmad, Sarfuddin Azmi, Monirah Abdulrahman Albabtain et al. · Pharmaceutics · 2026
ReviewOpen access · CC BYRead the open copy →
- Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence
Diana-Maria Mateescu, Ionuţ Dragoş Căpraru, Bogdan Enache et al. · Pharmaceutics · 2026
ReviewOpen access · CC BYRead the open copy →
- GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases
Elena Koceva, Gert N. Moll · European Journal of Pharmacology · 2026
ReviewOpen access · CC BYRead the open copy →
- Repurposing Retatrutide for Neuroprotection in Parkinson’s Disease: A Comprehensive Review
Sivakumar G., Thilagavathi K., Narmatha K. K. et al. · International Journal of Innovative Science and Research Technology (IJISRT) · 2026
Open accessRead the open copy →
- The metabolic paradigm shift in gastroenterology and hepatology: Clinical applications of incretin-based co-agonists
Abdulrahman Ismaiel, Dan Lucian Dumitrascu · Best Practice & Research Clinical Gastroenterology · 2026
Open access · CC BY-NCRead the open copy →
- Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide
Raphael M. Buzzi, Lars Christian Huber · BMJ Case Reports · 2026
Case reportOpen access · CC BY-NCRead the open copy →
- Dual and triple incretin agonists in type 2 diabetes: A new frontier in metabolic therapy
Syed Afzal Uddin Biyabani, Neelkantreddy Patil, Pooja V. Salimath et al. · International Journal of Pharmacy and Pharmaceutical Science · 2026
Open accessRead the open copy →
- GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity–Neurodegeneration Interface: A Narrative Review
Elena Popa, Andrei Emilian Popa, Vladimir Poroch et al. · International Journal of Molecular Sciences · 2026
ReviewOpen access · CC BYRead the open copy →
- Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents
Fnu Vikash, Muhammad Ehsan, Sara Osorio Valencia et al. · Nutrition in Clinical Practice · 2026
ReviewOpen access · CC BY-NCRead the open copy →
- Efficacy and Safety of Dual GLP ‐1/Glucagon Receptor Agonism in Overweight and Obesity: A Class‐Specific Systematic Review and Meta‐Analysis
Muhammad Maaz Amjad, Muhammad Mustafa Khan, Fatima Sarwar et al. · Diabetes Obesity and Metabolism · 2026
ReviewOpen accessRead the open copy →
- BEYOND GLYCEMIC CONTROL: ORGAN-PROTECTIVE EFFECTS AND SAFETY PROFILE OF GLP-1 RECEPTOR AGONISTS – A COMPREHENSIVE REVIEW
Magdalena Bukowska, Katarzyna Otrębska, Dominika Lewandowska et al. · International Journal of Innovative Technologies in Social Science · 2026
Open access · CC BYRead the open copy →
- Future GLP-1 receptor co-agonists and their cardiac effects
Joachim Neumann, Uwe Kirchhefer, Britt Hofmann et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 2026
Open access · CC BYRead the open copy →
- The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?
Maja Mizdrak, Darko Batistic, Ivan Mizdrak · Medical Sciences · 2026
ReviewOpen access · CC BYRead the open copy →
- Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats
Jonas Petersen, Christoffer Merrild, Stephanie Kjærulff Holm et al. · Nature Metabolism · 2026
Animal studyOpen access · CC BYRead the open copy →
- Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists
Dorota Bartkowiak, Barlomiej Jakubczyk, Adam Lasota et al. · Cureus · 2026
ReviewOpen access · CC BYRead the open copy →
- ADVANCES IN OBESITY PHARMACOTHERAPY: CURRENT STATE AND FUTURE PERSPECTIVES
Aleksandra Wielogórska, Olga Stasiak, Filip Kowalik et al. · International Journal of Innovative Technologies in Social Science · 2026
Open access · CC BYRead the open copy →
- Single or multiple nutritional hormone receptor modulators for chronic kidney disease
Hiddo J.L. Heerspink · Clinical Kidney Journal · 2026
ReviewOpen access · CC BY-NCRead the open copy →
- Incretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification
Yaeni Kim, Eun Young Lee, On behalf of the Korean Diabetic Kidney Disease Study Group · Kidney Research and Clinical Practice · 2026
Open access · CC BY-NC-NDRead the open copy →
- Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review
Irma Melyani Puspitasari, Dimas Setyadi Putra, Alifa Nisa Deliyana et al. · Diabetes Metabolic Syndrome and Obesity · 2026
ReviewOpen access · CC BY-NCRead the open copy →
- Pharmacological management of obesity: Current landscape and emerging therapies
Shubham Atal, Chirag Agrawal, Rahul Gupta et al. · Indian Journal of Pharmacology · 2026
ReviewOpen access · CC BY-NC-NDRead the open copy →
- Glucagon is terug: survodutide opent nieuw hoofdstuk in obesitas en MASLD
Marcel H.A. Muskiet · Nederlands Tijdschrift voor Diabetologie · 2026
Open access · CC BY-NC-NDRead the open copy →
Each list shows up to 40 papers.See all 337 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:30 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.